Sunovion pays $624M for Canada’s Cynapsus, lead PhIII Parkinson’s med

Sunovion Pharmaceuticals is to pay a 120% premium to buy out Canadian biotech Cynapsus Therapeutics as it looks to get its hands on the company’s late-stage Parkinson’s disease candidate.

Cynapsus ($CYNA) closed before the deal was announced at just over $18 a share, with Sunovion putting $40.50 a share, or $624 million, down for the drugmaker--a 120% premium over its closing price.

What’s the money going on? Predominately, its Phase III candidate, APL-130277, which is being tested as a sublingual thin film of apomorphine to manage so-called "off" episodes associated with PD, which see a major decrease in mobility.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

A pivotal Phase III trial is ongoing, but if successful, the company expects to file for an NDA for APL-130277 in the U.S. in the first half of next year.

A pivotal European clinical program which is looking at the safety and efficacy of APL-130277 in PD patients is also expected to begin in the fourth quarter of 2016--the same period the merger deal should be formally signed and sealed.

“Parkinson’s disease is a chronic, progressive neurodegenerative disease that affects more than four million people around the world, and there is a significant need for new options to treat the OFF episodes associated with it,” said Nobuhiko Tamura, chairman and CEO of Sunovion.

“We believe that APL-130277 is a novel late-stage candidate with the potential to make a real difference for patients and their families.”

Anthony Giovinazzo, president and CEO at Cynapsus, added: “With its leadership in therapies for central nervous system disorders and commercial experience specific to neurology, we believe Sunovion is best suited to advance APL-130277 in the United States and other key markets.

“This transaction culminates years of dedicated work by the Cynapsus team and represents significant value creation for our security holders.”

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.